Report cover image

Alzheimer’s Therapeutics Market

Publisher Future Market Insights
Published Apr 14, 2022
Length 363 Pages
SKU # FMARI17202817

Description

Alzheimer’s Therapeutics Market

A recent market study published by Future Market Insights (FMI) on the Alzheimer’s therapeutics market offers a global industry analysis for 2017-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the Alzheimer’s therapeutics market, the growth prospects of the market are obtained with maximum precision.

The report features unique and salient factors that may make a huge impact on the development of the Alzheimer’s therapeutics market during the forecast period. It can help market players modify their manufacturing and marketing strategies to envisage maximum growth in this market in the coming years.

The report provides detailed information about the current and future growth prospects of the Alzheimer’s therapeutics market in the most comprehensive way for a better understanding of readers.

Key Segments of Alzheimer’s Therapeutics Market

Future Market Insight study on the Alzheimer’s therapeutics market offers information divided into four important segments— drug name, drug class, distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug Name
Donepezil
Rivastigmine
Memantine
Galantamine
Manufactured Combination of Memantine and Donepezil
Drug Class
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Manufactured Combination
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Region
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa (MEA)
Chapter 1 – Executive Summary

The report commences with the executive summary of the Alzheimer’s therapeutics market report, which includes the summary of key findings and statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the Alzheimer’s therapeutics market as well as the key trends impacting the market.

Chapter 2 – Market Overview

Readers can find detailed taxonomy and definition/scope/limitations and inclusions and exclusions of the Alzheimer’s therapeutics market in this chapter, which helps readers understand basic information about the Alzheimer’s therapeutics market.

Chapter 3 – Key Market Trends

This section highlights the key trends impacting the Alzheimer’s therapeutics market, which will help readers in understanding the current trends and their impact on market growth.

Chapter 4 – Key Success Factors

This chapter explains the key success factors which include the treatment regime, disease epidemiology of Alzheimer’s disease, product adoption/ usage analysis by region, recent product approval, key promotional strategies by market players, regulatory scenario, pipeline assessment, Porter’s Analysis, PESTLE analysis, supply chain analysis, dosage patterns, and impact of Aduhelm Drug that are expected to augment the growth of the Alzheimer’s therapeutics market during the forecast period.

Chapter 5 – Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

This section explains the global market value or size analysis and forecast for the Alzheimer’s therapeutics market during the forecast period. Along with the historical market and opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2022), and an incremental $ opportunity for the forecast period (2022–2032).

Chapter 6 – Market Background

This chapter explains the key macroeconomic factors that are expected to influence the growth of the Alzheimer’s therapeutics market during the forecast period. The chapter also highlights the major forecast factors that will shape market growth. Besides, it provides key dynamics of the Alzheimer’s therapeutics market, which include the drivers, restraints, and opportunity analysis. This section also provides the current and expected impact of COVID-19 on the Alzheimer’s therapeutics market

Chapter 7– Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Drug Name

Based on drug name, the Alzheimer’s therapeutics market is segmented into drug names (donepezil, rivastigmine, memantine, galantamine and manufactured combination of memantine and donepezil). In this chapter, readers can find information about a detailed analysis of the market by different drugs available in the Alzheimer’s therapeutics market and their growth over the forecast period.

Chapter 8 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Class

Based on drug class, the Alzheimer’s therapeutics market is segmented into drug classes (cholinesterase Inhibitors, NMDA Receptor antagonists and manufactured combinations). In this chapter, readers can find information about a detailed analysis of the market by drug class available in the Alzheimer’s therapeutics market and their growth over the forecast period.

Chapter 9 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Distribution Channel

Based on distribution channels, the Alzheimer’s therapeutics market is segmented into hospital pharmacies, retail pharmacies, drug stores and online pharmacies. In this chapter, readers can find information about a detailed analysis of the market by different distribution channel available in the Alzheimer’s therapeutics market and their growth over the forecast period.

Chapter 10 – Global Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032, by Region

This chapter explains how the Alzheimer’s therapeutics market will grow across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania and the Middle East and Africa (MEA).

Chapter 11 – North America Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes a detailed analysis of the growth of the North America Alzheimer’s therapeutics market along with a country-wise assessment including the U.S. and Canada. Readers can also find key takeaways from this region, and market growth based on drug name, drug class, distribution channel and country of the Alzheimer’s therapeutics market in the North American region.

Chapter 12 – Latin America Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes the growth prospects of the Alzheimer’s therapeutics market in leading countries such as Brazil, Mexico, Argentina and the rest of Latin America. Readers can find thorough information about the growth parameters based on drug name, drug class, distribution channel and country in the Latin America Alzheimer’s therapeutics market during 2022-2032.

Chapter 13 – Europe Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter includes the growth prospects of the Alzheimer’s therapeutics market based on the development of new product development, regulatory approvals, and country in several European countries such as the U.K., Germany, France, Italy, Spain, Russia, and the Rest of Europe are included in this chapter.

Chapter 14 – East Asia Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

China, Japan, and South Korea are the prime subjects of assessment to obtain the growth prospects of the East Asia Alzheimer’s therapeutics market. Also, in this chapter, readers can find thorough information about the growth parameters of the East Asia Alzheimer’s therapeutics market through 2032.

Chapter 15 – South Asia Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

India, Thailand, Indonesia, Malaysia, and the rest of South Asia are the prime subjects of assessment to obtain the growth prospects of the Alzheimer’s therapeutics market. Also, in this chapter, readers can find thorough information about the growth parameters of the South Asia Alzheimer’s therapeutics market growth over the forecast period.

Chapter 16 – Oceania Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter consists of important parameters that have a huge impact on the growth of the Alzheimer’s therapeutics market in Oceania, based on market segmentation, during the forecast period. The chapter also provides an overview of the drivers, restraints, and trends in the Oceania Alzheimer’s therapeutics market.

Chapter 17 – Middle East and Africa Alzheimer’s Therapeutics Market Analysis 2017-2021 and Forecast 2022-2032

This chapter provides information on how the Alzheimer’s therapeutics market will grow in the major countries in the MEA region, such as GCC Countries, Turkey and the rest of MEA during 2022-2032.

Chapter 18 – Market Structure Analysis

This chapter highlights the tier structure analysis, market concentration analysis and company share analysis along with sales footprint analysis of key players operating in the Alzheimer’s therapeutics market.

Chapter 19 – Competition Analysis

In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the Alzheimer’s therapeutics market including company overview, revenue shares, strategic overview, and recent company developments. Some of the major market players featured in the report are Biogen Inc, AbbVie, Inc, Teva Pharmaceuticals Ltd, Eisai Co., Ltd., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc, Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd., Cipla Ltd., Torrent pharmaceuticals ltd., Unichem laboratories ltd, and Lannett Inc.

Chapter 20 – Assumptions and Acronyms Used

This chapter includes a list of acronyms and assumptions that provide a base for the information and statistics included in the report.

Chapter 21 – Research Methodology

This chapter helps readers understand the research methodology followed to obtain various conclusions, important qualitative information, and quantitative information about Alzheimer’s therapeutics market.

Sources and Primary Research Splits (%)

Industry Interactions
Key Designations

C - Level Executives
Marketing Directors
Product Managers
Business Development Officers
Production Managers
Procurement Heads
Sales Executives
Stakeholder Category

Distributors
Traders
Raw Material Suppliers
Industry Experts
References Catalogue
Industry Publications
World Health Organizations (WHO)
National Institute of Health (NIH)
Factiva
Company Press Releases
Annual Reports and Investor Presentations
Research Papers
Government Websites and Publications
Company Websites,
Morningstar
World bank Data
LinkedIn
Zoom info
Salesforce

Table of Contents

363 Pages
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation / Development Trends
4. Key Success Factors
4.1. Treatment Regime
4.2. Disease epidemiology of Alzheimer’s disease
4.3. Product Adoption/ Usage Analysis, by region
4.4. Recent Product Approval 
4.5. Key Promotional Strategies by Market Players
4.6. Regulatory Scenario
4.7. Pipeline Assessment
4.8. Porter’s Analysis
4.9. PESTLE Analysis
4.10. Supply Chain Analysis
4.11. Dosage Patterns
4.12. Impact of Aduhelm Drug
5. Global Alzheimer’s Therapeutics Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032
5.1. Historical Market Value (US$ Mn) Analysis, 2017–2021
5.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
6. Market Background
6.1. Macro-Economic Factors
6.1.1. Global Healthcare Spending Overview
6.1.2. Global Pharmaceutical Market Outlook
6.1.3. Global Prevalence of Dementia
6.2. Forecast Factors - Relevance & Impact
6.2.1. Rising ageing population
6.2.2. Growing investment in healthcare expenditure
6.2.3. Growing advancements in diagnostic technologies
6.2.4. Rising prevalence of neurodegenerative disease
6.2.5. Adverse effects may impact the market growth
6.2.6. Key Strategic Developments
6.2.7. Product Adoption Rate and Demand
6.2.8. New Product Launches
6.3. COVID-19 Crisis – Impact Assessment
6.3.1. COVID-19 Crisis Analysis
6.3.2. Current GDP Projection and Probable Impact
6.3.3. Short-Mid-Long Term Outlook 
6.3.4. Impact of COVID-19 on caregivers of Alzheimer’s disease
6.3.5. Impact of COVID-19 on Alzheimer’s disease diagnosis
6.4. Market Dynamics
6.4.1. Drivers
6.4.2. Restraints
6.4.3. Opportunity Analysis
6.5. Global Supply Demand Analysis
7. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Name
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis, By Drug Name, 2017–2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Name, 2022–2032
7.3.1. Donepezil
7.3.2. Rivastigmine
7.3.3. Memantine
7.3.4. Galantamine
7.3.5. Manufactured Combination of memantine and donepezil
7.4. Market Attractiveness Analysis, By Drug Name
8. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Drug Class 
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2017–2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2022–2032
8.3.1. Cholinesterase Inhibitors
8.3.2. NMDA Receptor Antagonists 
8.3.3. Manufactured Combination
8.4. Market Attractiveness Analysis, By Drug Class 
9. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, By Distribution Channel
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2017–2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Distribution Channel, 2022–2032
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Drug Stores
9.3.4. Online Pharmacies
9.4. Market Attractiveness Analysis, By Distribution Channel
10. Global Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis, By Region, 2017–2021
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2022–2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis, By Region
11. North America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
11.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Drug Name
11.3.3. By Drug Class
11.3.4. By Distribution Channel
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Drug Name
11.4.3. By Drug Class
11.4.4. By Distribution Channel
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis
11.7. Country Level Analysis & Forecast
11.7.1. U.S. Alzheimer’s Therapeutics Market Analysis
11.7.1.1. Introduction
11.7.1.2. Market Analysis and Forecast, By Market Taxonomy
11.7.1.2.1. By Drug Name
11.7.1.2.2. By Drug Class
11.7.1.2.3. By Distribution Channel
11.7.2. Canada Alzheimer’s Therapeutics Market Analysis
11.7.2.1. Introduction
11.7.2.2. Market Analysis and Forecast, By Market Taxonomy
11.7.2.2.1. By Drug Name
11.7.2.2.2. By Drug Class
11.7.2.2.3. By Distribution Channel
12. Latin America Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
12.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
12.3.1. By Country
12.3.1.1. Mexico
12.3.1.2. Brazil
12.3.1.3. Argentina
12.3.1.4. Rest of Latin America
12.3.2. By Drug Name
12.3.3. By Drug Class
12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Drug Name
12.4.3. By Drug Class
12.4.4. By Distribution Channel
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis
12.7. Country Level Analysis & Forecast
12.7.1. Mexico Alzheimer’s Therapeutics Market Analysis
12.7.1.1. Introduction
12.7.1.2. Market Analysis and Forecast, By Market Taxonomy
12.7.1.2.1. By Drug Name
12.7.1.2.2. By Drug Class
12.7.1.2.3. By Distribution Channel
12.7.2. Brazil Alzheimer’s Therapeutics Market Analysis
12.7.2.1. Introduction
12.7.2.2. Market Analysis and Forecast, By Market Taxonomy
12.7.2.2.1. By Drug Name
12.7.2.2.2. By Drug Class
12.7.2.2.3. By Distribution Channel
12.7.3. Argentina Alzheimer’s Therapeutics Market Analysis
12.7.3.1. Introduction
12.7.3.2. Market Analysis and Forecast, By Market Taxonomy
12.7.3.2.1. By Drug Name
12.7.3.2.2. By Drug Class
12.7.3.2.3. By Distribution Channel
13. Europe Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
13.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. Italy
13.3.1.3. France
13.3.1.4. U.K.
13.3.1.5. Spain
13.3.1.6. BENELUX
13.3.1.7. Nordic Countries
13.3.1.8. Russia
13.3.1.9. Rest of Europe
13.3.2. By Country
13.3.3. By Drug Name
13.3.4. By Drug Class
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Drug Name
13.4.3. By Drug Class
13.4.4. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country Level Analysis & Forecast
13.7.1. Germany Alzheimer’s Therapeutics Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, By Market Taxonomy
13.7.1.2.1. By Drug Name
13.7.1.2.2. By Drug Class
13.7.1.2.3. By Distribution Channel
13.7.2. Italy Alzheimer’s Therapeutics Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, By Market Taxonomy
13.7.2.2.1. By Drug Name
13.7.2.2.2. By Drug Class
13.7.2.2.3. By Distribution Channel
13.7.3. France Alzheimer’s Therapeutics Market Analysis
13.7.3.1. Introduction
13.7.3.2. Market Analysis and Forecast, By Market Taxonomy
13.7.3.2.1. By Drug Name
13.7.3.2.2. By Drug Class
13.7.3.2.3. By Distribution Channel
13.7.4. U.K. Alzheimer’s Therapeutics Market Analysis
13.7.4.1. Introduction
13.7.4.2. Market Analysis and Forecast, By Market Taxonomy
13.7.4.2.1. By Drug Name
13.7.4.2.2. By Drug Class
13.7.4.2.3. By Distribution Channel
13.7.5. Spain Alzheimer’s Therapeutics Market Analysis
13.7.5.1. Introduction
13.7.5.2. Market Analysis and Forecast, By Market Taxonomy
13.7.5.2.1. By Drug Name
13.7.5.2.2. By Drug Class
13.7.5.2.3. By Distribution Channel
13.7.6. BENELUX Alzheimer’s Therapeutics Market Analysis
13.7.6.1. Introduction
13.7.6.2. Market Analysis and Forecast, By Market Taxonomy
13.7.6.2.1. By Drug Name
13.7.6.2.2. By Drug Class
13.7.6.2.3. By Distribution Channel
13.7.7. Nordic Countries Alzheimer’s Therapeutics Market Analysis
13.7.7.1. Introduction
13.7.7.2. Market Analysis and Forecast, By Market Taxonomy
13.7.7.2.1. By Drug Name
13.7.7.2.2. By Drug Class
13.7.7.2.3. By Distribution Channel
13.7.8. Russia Alzheimer’s Therapeutics Market Analysis
13.7.8.1. Introduction
13.7.8.2. Market Analysis and Forecast, By Market Taxonomy
13.7.8.2.1. By Drug Name
13.7.8.2.2. By Drug Class
13.7.8.2.3. By Distribution Channel
14. East Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
14.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
14.3.1. By Country
14.3.1.1. China
14.3.1.2. Japan
14.3.1.3. South Korea
14.3.2. By Country
14.3.3. By Drug Name
14.3.4. By Drug Class
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Drug Name
14.4.3. By Drug Class
14.4.4. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. China Alzheimer’s Therapeutics Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, By Market Taxonomy
14.7.1.2.1. By Drug Name
14.7.1.2.2. By Drug Class
14.7.1.2.3. By Distribution Channel
14.7.2. Japan Alzheimer’s Therapeutics Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, By Market Taxonomy
14.7.2.2.1. By Drug Name
14.7.2.2.2. By Drug Class
14.7.2.2.3. By Distribution Channel
14.7.3. South Korea Alzheimer’s Therapeutics Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, By Market Taxonomy
14.7.3.2.1. By Drug Name
14.7.3.2.2. By Drug Class
14.7.3.2.3. By Distribution Channel
15. South Asia Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
15.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Thailand
15.3.1.3. Malaysia
15.3.1.4. Philippines
15.3.1.5. Indonesia
15.3.1.6. Vietnam
15.3.1.7. Rest of South Asia
15.3.2. By Drug Name
15.3.3. By Drug Class
15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Drug Name
15.4.3. By Drug Class
15.4.4. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. India Alzheimer’s Therapeutics Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, By Market Taxonomy
15.7.1.2.1. By Drug Name
15.7.1.2.2. By Drug Class
15.7.1.2.3. By Distribution Channel
15.7.2. Thailand Alzheimer’s Therapeutics Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, By Market Taxonomy
15.7.2.2.1. By Drug Name
15.7.2.2.2. By Drug Class
15.7.2.2.3. By Distribution Channel
15.7.3. Malaysia Alzheimer’s Therapeutics Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, By Market Taxonomy
15.7.3.2.1. By Drug Name
15.7.3.2.2. By Drug Class
15.7.3.2.3. By Distribution Channel
15.7.4. Philippines Alzheimer’s Therapeutics Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, By Market Taxonomy
15.7.4.2.1. By Drug Name
15.7.4.2.2. By Drug Class
15.7.4.2.3. By Distribution Channel
15.7.5. Indonesia Alzheimer’s Therapeutics Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast, By Market Taxonomy
15.7.5.2.1. By Drug Name
15.7.5.2.2. By Drug Class
15.7.5.2.3. By Distribution Channel
15.7.6. Vietnam Alzheimer’s Therapeutics Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast, By Market Taxonomy
15.7.6.2.1. By Drug Name
15.7.6.2.2. By Drug Class
15.7.6.2.3. By Distribution Channel
15.7.7. Rest of South Asia Alzheimer’s Therapeutics Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast, By Market Taxonomy
15.7.7.2.1. By Drug Name
15.7.7.2.2. By Drug Class
15.7.7.2.3. By Distribution Channel
16. Oceania Alzheimer’s Therapeutics Market 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
16.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
   16.3.1. By Country
16.3.2. Australia
16.3.3. New Zealand
16.3.4. By Drug Name
16.3.5.  By Drug Class
16.3.6. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Drug Name
16.4.3. By Drug Class
16.4.4. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. Australia Alzheimer’s Therapeutics Market Analysis
16.7.2.Introduction
16.7.3. Market Analysis and Forecast, By Market Taxonomy
16.7.3.1. By Drug Name
16.7.3.2.By Drug Class
16.7.3.3. By Distribution Channel
16.7.2. New Zealand Alzheimer’s Therapeutics Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, By Market Taxonomy
16.7.2.2.1. By Drug Name
16.7.2.2.2. By Drug Class
16.7.2.2.3. By Distribution Channel
17. Middle East and Africa (MEA) Alzheimer’s Therapeutics Market Analysis 2017–2021 and Forecast 2022–2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis Trend Analysis, By Market Taxonomy, 2017–2021
17.3. Market Size (US$ Mn) Analysis Forecast, By Market Taxonomy, 2022–2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. Israel
17.3.1.3. Turkey
17.3.1.4. South Africa 
17.3.1.5. North Africa
17.3.1.6. Rest of Middle East and Africa
17.3.2. By Drug Name
17.3.3. By Drug Class
17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Drug Name
17.4.3. By Drug Class
17.4.4. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. GCC Countries Alzheimer’s Therapeutics Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, By Market Taxonomy
17.7.1.2.1. By Drug Name
17.7.1.2.2. By Drug Class
17.7.1.2.3. By Distribution Channel
17.7.2. Israel Alzheimer’s Therapeutics Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, By Market Taxonomy
17.7.2.2.1. By Drug Name
17.7.2.2.2. By Drug Class
17.7.2.2.3. By Distribution Channel
17.7.3. Turkey Alzheimer’s Therapeutics Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, By Market Taxonomy
17.7.3.2.1. By Drug Name
17.7.3.2.2. By Drug Class
17.7.3.2.3. By Distribution Channel
17.7.4. South Africa Alzheimer’s Therapeutics Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, By Market Taxonomy
17.7.4.2.1. By Drug Name
17.7.4.2.2. By Drug Class
17.7.4.2.3. By Distribution Channel
17.7.5. North Africa Alzheimer’s Therapeutics Market Analysis
17.7.5.1. Introduction
17.7.5.2. Market Analysis and Forecast, By Market Taxonomy
17.7.5.2.1. By Drug Name
17.7.5.2.2. By Drug Class
17.7.5.2.3. By Distribution Channel
17.7.6. Rest of MEA Alzheimer’s Therapeutics Market Analysis
17.7.6.1. Introduction
17.7.6.2. Market Analysis and Forecast, By Market Taxonomy
17.7.6.2.1. By Drug Name
17.7.6.2.2. By Drug Class
17.7.6.2.3. By Distribution Channel
18. Market Structure Analysis
18.1. Market Analysis, By Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
19. Competition Analysis
19.1. Competition Dashboard
19.2. Key Development Analysis
19.3. Competition Benchmarking
19.4. Competition Deep Dive 
19.4.1. Biogen Inc. 
19.4.1.1. Overview
19.4.1.2. Product Portfolio
19.4.1.3. Profitability by Market Segments (Product/Channel/Region)
19.4.1.4. Sales Footprint
19.4.1.5. Strategy Overview
19.4.2. AbbVie, Inc.
19.4.2.1. Overview
19.4.2.2. Product Portfolio
19.4.2.3. Profitability by Market Segments (Product/Channel/Region)
19.4.2.4. Sales Footprint
19.4.2.5. Strategy Overview
19.4.3. Teva Pharmaceuticals Ltd.
19.4.3.1. Overview
19.4.3.2. Product Portfolio
19.4.3.3. Profitability by Market Segments (Product/Channel/Region)
19.4.3.4. Sales Footprint
19.4.3.5. Strategy Overview
19.4.4. Eisai Co., Ltd.
19.4.4.1. Overview
19.4.4.2. Product Portfolio
19.4.4.3. Profitability by Market Segments (Product/Channel/Region)
19.4.4.4. Sales Footprint
19.4.4.5. Strategy Overview
19.4.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
19.4.5.1. Overview
19.4.5.2. Product Portfolio
19.4.5.3. Profitability by Market Segments (Product/Channel/Region)
19.4.5.4. Sales Footprint
19.4.5.5. Strategy Overview
19.4.6. Novartis AG
19.4.6.1. Overview
19.4.6.2. Product Portfolio
19.4.6.3. Profitability by Market Segments (Product/Channel/Region)
19.4.6.4. Sales Footprint
19.4.6.5. Strategy Overview
19.4.7. Zydus Lifesciences Ltd (CADILA)
19.4.7.1. Overview
19.4.7.2. Product Portfolio
19.4.7.3. Profitability by Market Segments (Product/Channel/Region)
19.4.7.4. Sales Footprint
19.4.7.5. Strategy Overview
19.4.8. Sun Pharmaceutical Industries Ltd.
19.4.8.1. Overview
19.4.8.2. Product Portfolio
19.4.8.3. Profitability by Market Segments (Product/Channel/Region)
19.4.8.4. Sales Footprint
19.4.8.5. Strategy Overview
19.4.9. Dr. Reddy's Laboratories Ltd
19.4.9.1. Overview
19.4.9.2. Product Portfolio
19.4.9.3. Profitability by Market Segments (Product/Channel/Region)
19.4.9.4. Sales Footprint
19.4.9.5. Strategy Overview
19.4.10. Aurobindo Pharma Ltd
19.4.10.1. Overview
19.4.10.2. Product Portfolio
19.4.10.3. Profitability by Market Segments (Product/Channel/Region)
19.4.10.4. Sales Footprint
19.4.10.5. Strategy Overview
19.4.11. Amneal Pharmaceuticals Inc.
19.4.11.1. Overview
19.4.11.2. Product Portfolio
19.4.11.3. Profitability by Market Segments (Product/Channel/Region)
19.4.11.4. Sales Footprint
19.4.11.5. Strategy Overview
19.4.12. Macleods Pharmaceuticals Ltd.
19.4.12.1. Overview
19.4.12.2. Product Portfolio
19.4.12.3. Profitability by Market Segments (Product/Channel/Region)
19.4.12.4. Sales Footprint
19.4.12.5. Strategy Overview
19.4.13. Viatris Inc.
19.4.13.1. Overview
19.4.13.2. Product Portfolio
19.4.13.3. Profitability by Market Segments (Product/Channel/Region)
19.4.13.4. Sales Footprint
19.4.13.5. Strategy Overview
19.4.14. Lupin Ltd
19.4.14.1. Overview
19.4.14.2. Product Portfolio
19.4.14.3. Profitability by Market Segments (Product/Channel/Region)
19.4.14.4. Sales Footprint
19.4.14.5. Strategy Overview
19.4.15. Cipla Ltd.
19.4.15.1. Overview
19.4.15.2. Product Portfolio
19.4.15.3. Profitability by Market Segments (Product/Channel/Region)
19.4.15.4. Sales Footprint
19.4.15.5. Strategy Overview
19.4.16. Torrent pharmaceuticals ltd.
19.4.16.1. Overview
19.4.16.2. Product Portfolio
19.4.16.3. Profitability by Market Segments (Product/Channel/Region)
19.4.16.4. Sales Footprint
19.4.16.5. Strategy Overview
19.4.17. Unichem laboratories ltd
19.4.17.1. Overview
19.4.17.2. Product Portfolio
19.4.17.3. Profitability by Market Segments (Product/Channel/Region)
19.4.17.4. Sales Footprint
19.4.17.5. Strategy Overview
19.4.18. Lannett Inc.
19.4.18.1. Overview
19.4.18.2. Product Portfolio
19.4.18.3. Profitability by Market Segments (Product/Channel/Region)
19.4.18.4. Sales Footprint
19.4.18.5. Strategy Overview
20. Assumptions and Acronyms Used
21. Research Methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us